Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 6/20 | 0.71 |
| ▸ | ADK | P55263 | 3/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597658 | 1.00 | METTL3 (0.71) | METTL3ADKPRMT5SLC29A1DPP4 | |
| SCHEMBL10079498 | 1.00 | METTL3 (0.71) | METTL3ADKPRMT5SLC29A1DPP4 | |
| SCHEMBL15948766 | 1.00 | METTL3 (0.71) | METTL3ADKPRMT5SLC29A1DPP4 | |
| SCHEMBL25413618 | 1.00 | METTL3 (0.71) | METTL3ADKPRMT5SLC29A1DPP4 | |
| SCHEMBL14429030 | 0.95 | ADK (0.67) | METTL3ADKPRMT5SLC29A1 | |
| SCHEMBL14429083 | 0.95 | ADK (0.67) | METTL3ADKPRMT5SLC29A1 | |
| SCHEMBL1738522 | 0.91 | ADK (0.69) | METTL3ADKPRMT5SLC29A1 | |
| Tubercidin SCHEMBL23351430 | 0.89 | ADK (0.82) | ADKSLC29A1DPP4 | |
| Tubercidin SCHEMBL20419325 | 0.89 | ADK (0.82) | ADKSLC29A1DPP4 | |
| Tubercidin SCHEMBL23982350 | 0.89 | ADK (0.82) | ADKSLC29A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20120010164-A1 | ANTIVIRAL AGENTS | SURNMA VINCENZO (IT) | 2012-01-12 | — | — | US | disclosed |
| US-20120010164-A1 | ANTIVIRAL AGENTS | SURNMA VINCENZO (IT) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | METTL3 861/4885ADK 959/4885PRMT5 2506/4885 |
| US-20120010164-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | METTL3 2422/4885ADK 2649/4885PRMT5 3704/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | METTL3 4407/4885ADK 471/4885PRMT5 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.